Evidence map›Paper›PMID 28892388›Full record

ArticleJournal of medicinal chemistry2017

Novel Radiolabeled Vanilloid with Enhanced Specificity for Human Transient Receptor Potential Vanilloid 1 (TRPV1).

Larry V Pearce, Jihyae Ann, Aeran Jung, Shivaji A Thorat, Brienna K A Herold, Amelework D Habtemichael, Peter M Blumberg, Jeewoo Lee

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Larry V PearceLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH , Bethesda, Maryland 20892-4255, United States.
Jihyae AnnLaboratory of Medicinal Chemistry, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University , Seoul 08826, Republic of Korea.
Aeran JungLaboratory of Medicinal Chemistry, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University , Seoul 08826, Republic of Korea.
Shivaji A ThoratLaboratory of Medicinal Chemistry, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University , Seoul 08826, Republic of Korea.
Brienna K A HeroldLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH , Bethesda, Maryland 20892-4255, United States.
Amelework D HabtemichaelLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH , Bethesda, Maryland 20892-4255, United States.
Peter M BlumbergLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH , Bethesda, Maryland 20892-4255, United States.
Jeewoo LeeLaboratory of Medicinal Chemistry, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University , Seoul 08826, Republic of Korea.ORCID 0000-0002-7832-6719
National Cancer Institute · USSeoul National University · KR

Funding

Molecular Mechanism of Action of Phorbol EsterZIABC005270 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BLUMBERG, PETER · 2009 to 2018
$18.4M
MOLECULAR MECHANISM OF ACTION OF PHORBOL ESTER TUMOR PROMOTERSZ01BC005270 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BLUMBERG, PETER · 1996 to 2008
$4.3M
Intramural NIH HHS Z01 BC005270
6 · The paper itself

Abstract

Transient receptor potential vanilloid 1 (TRPV1) has emerged as a promising therapeutic target. While radiolabeled resiniferatoxin (RTX) has provided a powerful tool for characterization of vanilloid binding to TRPV1, TRPV1 shows 20-fold weaker binding to the human TRPV1 than to the rodent TRPV1. We now describe a tritium radiolabeled synthetic vanilloid antagonist, 1-((2-(4-(methyl-[

Indexed as

AnimalsBenzoxazinesBinding SitesHumansProtein BindingRatsStructure-Activity RelationshipSubstrate SpecificityTRPV Cation ChannelsUrea1-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)methyl)-3-(3-oxo-3,4-dihydro-2H-benzo(b)(1,4)oxazin-8-yl)ureaBenzoxazinesTRPV1 protein, humanTRPV Cation ChannelsUrea

Identifiers

PMID28892388
PMCPMC6959550
OpenAlexW2755728068

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.